Related Experiment Video
Updated: Oct 12, 2025
11:15
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.3K
Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
Viviana De Martino1, Michela Rossi2, Giulia Battafarano2
1Department of Clinical, Internal, Anaesthesiology and Cardiovascular Sciences, Sapienza University, 00185 Rome, Italy.
International Journal of Molecular Sciences
|November 27, 2021
Summary
Extracellular vesicles (EVs) are key regulators in osteosarcoma (OS) progression and metastasis. Characterizing these EVs could lead to new diagnostic and therapeutic strategies for this challenging bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) is a primary bone cancer predominantly affecting children and adolescents.
- Lung metastasis is a frequent complication of OS, leading to poor patient outcomes.
- Current treatments like surgery and chemotherapy face challenges due to drug resistance and side effects.
Purpose of the Study:
- To explore the role of extracellular vesicles (EVs) in osteosarcoma.
- To investigate EVs as potential diagnostic and prognostic biomarkers for OS.
- To assess the therapeutic potential of EVs in osteosarcoma treatment.
Main Methods:
- Review and synthesis of current literature on osteosarcoma and extracellular vesicles.
- Analysis of the biological functions of EVs in the tumor microenvironment.
- Evaluation of circulating EVs as biomarkers and drug delivery vehicles.
Main Results:
- Extracellular vesicles (EVs) significantly regulate tumor proliferation and metastasis in osteosarcoma.
- Circulating EVs show promise as non-invasive diagnostic and prognostic markers.
- EVs can be engineered for targeted drug delivery, offering a novel therapeutic avenue.
Conclusions:
- Understanding osteosarcoma-derived EVs is crucial for developing innovative treatments.
- EVs can be repurposed from disease drivers to therapeutic and diagnostic tools.
- Targeting EVs represents a promising strategy to overcome therapeutic limitations in osteosarcoma.
Related Concept Videos
01:19Mesenchymal Stem Cells
5.1K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.1K
01:36Overview of Exosomes
2.9K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.9K
01:15Receptor Downregulation in MVBs
2.3K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.3K